CN Patent

CN101626758A — 用于治疗癌症的lbh589和其他治疗剂的组合

Assigned to Novartis AG · Expires 2010-01-13 · 16y expired

What this patent protects

本发明涉及包含N－羟基－3－[4－[[[2－(2－甲基－1H－吲哚－3－基)－乙基]－氨基]甲基]苯基]－2E－2－丙烯酰胺和一种或多种药学活性剂的组合；包含所述组合的药物组合物；包括所述组合的治疗方法；制备所述组合的方法；以及包含所述组合的商业包装。

USPTO Abstract

本发明涉及包含N－羟基－3－[4－[[[2－(2－甲基－1H－吲哚－3－基)－乙基]－氨基]甲基]苯基]－2E－2－丙烯酰胺和一种或多种药学活性剂的组合；包含所述组合的药物组合物；包括所述组合的治疗方法；制备所述组合的方法；以及包含所述组合的商业包装。

Drugs covered by this patent

Patent Metadata

Patent number
CN101626758A
Jurisdiction
CN
Classification
—
Expires
2010-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.